Virpax Pharmaceuticals Bolsa (NASDAQ: VRPX)

Últimas noticias sobre Virpax Pharmaceuticals (NASDAQ:VRPX) Bolsa

Virpax Pharmaceuticals

Virpax Pharmaceuticals Inc is a preclinical stage biopharmaceutical company. The company is focused on developing pharmaceutical product candidates for pain management. Its product portfolio includes Topical metered-dose spray; Liposomal in Hydrogel encapsulation; and Enkephalin Intranasal spray.

Virpax Pharmaceuticals, Inc. - Common Stock

Virpax Pharmaceuticals Inc

REE Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REE#NASDAQ">REE</a>) just disclosed its Q3 earnings on Tuesday, December 17, 2024 at 07:15 AM.
Here's a brief overview of the earnings report.
<h3>Earnings</h3>
REE Automotive missed estimated earnings by -30.0%, reporting an EPS of $-1.12 versus an estimate of $-0.86.
Revenue was down $199 thousand from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company beat on EPS by $0.54 which was followed by a 18.0% increase in the share price the next day.

To track all earnings releases for REE Automotive <a href="https://www.benzinga.com/quote/REE/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

Insights into REE Automotive Q3 Earnings

News

MNTS

Momentus To Deploy DoD And Commercial Payloads On SpaceX Rideshare Mission In 2026 Using Vigoride Orbital Service Vehicle, Offering Cost-Effective LEO Deployment And Hosted Payload Services

Cantor Fitzgerald analyst Prakhar Agrawal initiates coverage on TriSalus Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLSI#NASDAQ">TLSI</a>) with a Overweight rating and announces Price Target of $10.

Price Target

Initiation

Analyst Ratings

TLSI

Cantor Fitzgerald Initiates Coverage On TriSalus Life Sciences with Overweight Rating, Announces Price Target of $10

GELS

Gelteq Announces FDA Approval Of Its Suitability Petition For Its Animal Drug Under Development

BYRN

Byrna Technolofiw To Increase Launcher Production By 33%

Guidance

Bank Of America CEO Moynihan Says Real Rate Structures Have To Come Down A Little Bit To Have More Normalcy In The System; We Don't Expect Medium Term Rates Structure To Move Down A Lot

JAGX

Jaguar Health's  Napo Pharmaceuticals Announces FDA Orphan Drug Designation For Crofelemer

Wedbush analyst Matt Bryson reiterates Micron Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) with a Outperform and maintains $140 price target.

Reiteration

Wedbush Reiterates Outperform on Micron Technology, Maintains $140 Price Target

WIIM

MRKR

Marker Therapeutics shares are trading higher after the company announced it won a $9.5 million grant to study pancreatic cancer therapy.

New decision establishes reimbursement for the clinical use of Tempus ECG-AF, reducing the financial burden of using AI to improve early detection of atrial fibrillation

Biotech

General

Tempus AI announced CMS Decision That Will Allow Reimbursement Assessments Of Cardiax Dysfunctions Using Tempus ECG-AF Algorithm.

Barclays analyst Richard Hightower initiates coverage on UDR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UDR#NYSE">UDR</a>) with a Overweight rating and announces Price Target of $50.

Barclays Initiates Coverage On UDR with Overweight Rating, Announces Price Target of $50

LPTH

LightPath Technologies Highlights Strategic Shift To Advanced Optics And Imaging Systems, Defense Growth With $500M-$1B U.S. Army Missile Project, Black Diamond Glass Innovation, Commercial Expansion With Mantis Camera, And Leadership Enhancements For Global Expansion

Wedbush analyst Robert Driscoll reiterates IDEAYA Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDYA#NASDAQ">IDYA</a>) with a Outperform and maintains $52 price target.

IDYA

Wedbush Reiterates Outperform on IDEAYA Biosciences, Maintains $52 Price Target

PLCE

The Children's Place Reports Prelim Results, Reports Net Sales For Six-Week Period Ending Dec. 14 Increased 3.4%; Comparable Retail Sales Decreased 8.9%

RMNI

Rimini Street shares are trading higher after Craig-Hallum upgraded the stock from Hold to Buy and raised its price target from $2 to $6.

Ashford Hospitality Trust shares are trading higher after the company announced it launched strategic initiatives and is targeting $50 million of EBITDA improvement.

Macro Economic Events

Econ #s

Economics

Retail Sales Ex Gas/Autos (MoM) (Nov) +0.2% vs +0.4%; +0.2% Prior

U.S. President-elect Donald Trump is set to meet Netflix&nbsp;Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) co-CEO Ted Sarandos on Tuesday at Trump&#8217;s Mar-a-Lago resort, Reuters cites familiar sources.
Reuters, citing researcher OpenSecrets said Sarandos has traditionally backed Democratic Party candidates by donating to support them.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42514598/hubspots-ai-powered-tools-set-to-drive-smb-growth-and-crm-innovation-analyst-says" rel="noreferrer noopener">HubSpot To Dominate SMB CRM Space With AI-Driven Platform, Says BofA Analyst</a>
Let us examine the dynamics between the streaming giant and the U.S. government. Netflix co-founder Reed Hastings had <a target="_blank" href="https://www.benzinga.com/news/24/07/39932764/kamala-harris-presidential-campaign-secures-7m-from-netflix-co-founder-reed-hastings" rel="noreferrer noopener">committed a record $7 million</a> to a super PAC backing Vice President Kamala Harris&#8217; presidential campaign.
Hastings&#8217; contribution marks his largest single donation to a candidate. Although initially hesitant to endorse Harris following President Joe Biden&#8217;s withdrawal. This pledge followed Harris&#8217; impressive fundraising momentum.
In July, Netflix reportedly experienced a sharp rise in subscription cancellations after Hastings <a target="_blank" href="https://www.benzinga.com/general/entertainment/24/09/41084606/elon-musk-targets-lopsided-anti-trump-donations-by-netflix-employees-as-cancellations-soare" rel="noreferrer noopener">declared his support for Harris</a>.
Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) and SpaceX CEO Elon Musk drew attention to the news, pointing to claims of political donation bias among Netflix employees. Bloomberg columnist Lucas Shaw, citing research firm Antenna, reported that Netflix&#8217;s U.S. cancellation rate nearly tripled after Hastings publicly endorsed Harris.
In 2022, three Democratic senators urged Netflix to reduce smoking and vaping depictions <a target="_blank" href="https://www.benzinga.com/general/entertainment/22/04/26429457/senators-demand-netflix-reduce-scenes-with-smoking-vaping" rel="noreferrer noopener">in its streaming content</a>.&nbsp;&nbsp;
Sens. Ed Markey (D-MA), Chris Van Hollen (D-MD), and Richard Blumenthal (D-CT) wrote to Netflix co-CEOs Reed Hastings and Ted Sarandos, requesting fewer scenes featuring smoking and vaping in shows and films.
The senators referenced a Truth Initiative report, which found that Netflix&#8217;s content—popular among young audiences—has shown more smoking or vaping scenes than any other channel over the past four years.
Shows like The Queen&#8217;s Gambit and The Umbrella Academy were cited for having over 200 instances of smoking or vaping in their respective 2020 seasons.
Last week, Trump shared plans to meet with Amazon.com Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) founder Jeff Bezos.
Netflix stock surged 96% year-to-date, backed by its diverse content and live events, including the highly expected&nbsp;NFL Christmas Day games. Oppenheimer&#8217;s Jason Helfstein hailed Netflix as the sole investable <a target="_blank" href="https://www.benzinga.com/general/sports/24/12/42512587/netflix-analyst-say-its-only-investable-media-stock-projects-150-million-nfl-christmas-day-boost" rel="noreferrer noopener">mainstream media stock</a>. The analyst flagged a $2.2 billion advertising opportunity annually for live events.
Price Action: NFLX stock traded lower by 0.11% to $920.04 premarket at the last check on Tuesday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42514450/grindrs-expanding-lgbtq-market-and-20-revenue-growth-impresses-goldman-sachs" target="_blank" rel="noreferrer noopener">Grindr&#8217;s Expanding LGBTQ+ Market and 20% Revenue Growth Impresses Goldman Sachs</a></li>
</ul>
Image via Shutterstock

Government

Tech

Media

AMZN

NFLX

TSLA

Trump and Netflix Boss Sarandos Set for High-Stakes Mar-a-Lago Meeting

USA Retail Sales (MoM) For November +0.7% Vs 0.6% Est.; 0.5% Prior

Macro Notification

US Core Retail Sales (MoM) (Nov)	+0.2% vs +0.4% Est.; +0.2% Prior

Virpax Pharmaceuticals ( ($VRPX) ) just unveiled an update. Virpax Pharmaceuticals has been notified by Nasdaq of not meeting the minimum bid price...

Virpax Pharmaceuticals Faces Nasdaq Delisting Risk

Warning: VRPX is at high risk of performing badly

Adial Pharmaceuticals (ADIL) announced the appointment of Vinay Shah as the Company's Chief Financial Officer, effective November 16, 2024. Most re...

Adial Pharmaceuticals appoints Shah as Chief Financial Officer

The latest announcement is out from Virpax Pharmaceuticals ( ($VRPX) ). Virpax Pharmaceuticals has announced a $5 million public offering of common...

Virpax Pharmaceuticals Announces $5M Public Offering

An announcement from Virpax Pharmaceuticals ( ($VRPX) ) is now available. Virpax Pharmaceuticals has appointed Usama Chaudhry as Chief Financial Of...

Virpax Pharmaceuticals Announces New Chief Financial Officer

Virpax Pharmaceuticals (VRPX) announced that it has been granted an extension of its cooperative research and development agreement with the Nation...

Virpax Pharmaceuticals announces HHS pact over NES100 developmental extension

Virpax Pharmaceuticals (VRPX) announced results from a minipig dose range finding, or DRF, study for Probudur. Probudur is the company's long-actin...

Virpax Pharmaceuticals announces results from Probudur minipig DRF study

Virpax Pharmaceuticals ( ($VRPX) ) has issued an update. Virpax Pharmaceuticals, Inc. has taken significant steps to enhance its governance and str...

Virpax Pharmaceuticals Strengthens Leadership and Expands Collaborations

Palladyne AI Corp., SKK Holdings Ltd., and Virpax Pharmaceuticals are the 3&nbsp;Penny Stocks&nbsp;to watch on November 26, 2024, based on&nbsp;Tip...

3 Penny Stocks to Watch Now, 11/26/24

An announcement from Virpax Pharmaceuticals ( ($VRPX) ) is now available. Virpax Pharmaceuticals announced the resignation of Mr. Gary Herman from ...

Virpax Pharmaceuticals Announces Board Member Resignation

ADIL

PDYN

VRPX

Press Releases

Virpax Announces Positive Results of Swine Model Pilot Study for Probudur™

Virpax Regains Compliance with Nasdaq Minimum Bid Price

Virpax Pharmaceuticals to Present at Sidoti Virtual Investor Conference August 14-15

Virpax Pharmaceuticals Reports 2024 Second Quarter Results and Recent Developments

Management

Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer

Virpax Pharmaceuticals, Inc. Announces Pricing of $5.0 Million Public Offering of Common Stock and Pre-Funded Warrants

Virpax Pharmaceuticals, Inc. Announces Closing of $5.0 Million Public Offering of Common Stock and Pre-Funded Warrants

Spartan Capital Securities, LLC Serves as Sole Placement Agent in Virpax Pharmaceuticals, Inc.'s $5.0 Million Public Offering

Virpax Announces Agreement with the U.S. Department of Health and Human Services for the Developmental Extension for NES100 Towards IND for Acute and Chronic Non-Cancer Pain Alternative

Virpax Announces Positive Results for the Swine Model Dose Range Finding Study for Probudur™

Comments

Virpax Pharmaceuticals

Noticias

Últimas noticias sobre Virpax Pharmaceuticals (NASDAQ:VRPX) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL